Obtaining additional biomarker support for an underlying synucleinopathy, through skin biopsy for phosphorylated synuclein55 or alpha‐synuclein CSF SAA testing,56 can aid in informed decision making. This evidence concerns the gene SNCA and synucleinopathy.